PHVS deucrictibant XR cuts HAE attack rates by 83%
Phase III CHAPTER-3 results for deucrictibant XR in HAE show attack rates reduced 83% versus placebo, with nearly half of treated patients remaining attack-free over 24 weeks. Therapy was well-tolerated and improved quality of life.
Story updates
01:57:49 PM UTC
SquawkNews
PHVS: Deucrictibant XR cut HAE attacks by 83% and kept nearly half of patients attack-free for 24 weeks
The phase III CHAPTER-3 study found that deucrictibant XR significantly reduced HAE attack rates by 83% versus placebo, with nearly half of treated patients remaining attack-free over 24 weeks. The oral therapy was well-tolerated, improved quality of life and was described as a promising alternative to injectable treatment.